Data / Research funding / Massachusetts / Reveal Pharma
Reveal Pharma: 6 NIH awards ($11.7M), fiscal years 2021 to 2026
Reveal Pharma in Cambridge, MA is funded under 6 NIH awards ($11.7M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- LAS2A8MTAR45
- State
- Massachusetts
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Manganese Based MRI Contrast Agent | NIH | National Cancer Institute | 2023 to 2024 | $4,050,000 | June 5, 2023 | May 31, 2026 | HOFFMAN, VERA | reporter.nih.gov |
| Fibrogenesis Targeted Manganese Based MRI Contrast Agent | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,239,969 | September 15, 2022 | August 31, 2025 | HOFFMAN, VERA | reporter.nih.gov |
| Manganese-based Contrast Agent for Cardiovascular MRI | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,057,361 | December 15, 2020 | May 31, 2026 | HOFFMAN, VERA | reporter.nih.gov |
| Manganese Based MRI Contrast Agent - First In Human Clinical Trial | NIH | National Cancer Institute | 2021 to 2022 | $2,053,452 | September 24, 2021 | December 31, 2023 | HOFFMAN, VERA | reporter.nih.gov |
| Liver Specific Manganese Based MRI Contrast Agent | NIH | National Cancer Institute | 2021 | $999,330 | August 8, 2019 | September 30, 2022 | HOFFMAN, VERA | reporter.nih.gov |
| Manganese-based Contrast Agent for Cardiovascular MRI | NIH | National Heart, Lung, and Blood Institute | 2021 | $300,000 | December 15, 2020 | December 14, 2022 | HOFFMAN, VERA | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2024 | 3 | $4,025,160 | 0 | $0 |
| 2023 | 3 | $4,031,760 | 0 | $0 |
| 2022 | 2 | $1,193,922 | 0 | $0 |
| 2021 | 3 | $2,449,270 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.395 | November 2, 2026 | Not listed | Same assistance listing 93.395 as 2 awards here |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) | PAR-26-152 | NIH | 93.395 | November 11, 2026 | Not listed | Same assistance listing 93.395 as 2 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.395 | November 20, 2026 | Not listed | Same assistance listing 93.395 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.837 | December 3, 2026 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.837 | December 3, 2026 | Not listed | Same assistance listing 93.837 as 2 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.837 | December 4, 2026 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.837 | January 5, 2027 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.837 | January 5, 2027 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.837 | January 7, 2027 | $375,000 | Same assistance listing 93.837 as 2 awards here |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | PAR-25-079 | NIH | 93.395 | January 7, 2027 | $500,000 | Same assistance listing 93.395 as 2 awards here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.395 | January 7, 2027 | $499,999 | Same assistance listing 93.395 as 2 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.837 | January 7, 2027 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) | RFA-CA-27-005 | NIH | 93.395 | January 11, 2027 | $700,000 | Same assistance listing 93.395 as 2 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 2 awards here |
| Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) | RFA-CA-26-010 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 2 awards here |
| Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) | RFA-CA-27-003 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 2 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) | PAR-25-025 | NIH | 93.837 | February 3, 2027 | $1.5 million | Same assistance listing 93.837 as 2 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) | PAR-25-026 | NIH | 93.837 | February 3, 2027 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-27-125 | NIH | 93.837 | February 16, 2027 | Not listed | Same assistance listing 93.837 as 2 awards here |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) | RFA-DK-27-108 | NIH | 93.837 | March 10, 2027 | $500,000 | Same assistance listing 93.837 as 2 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.